Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- Drug Pricing Rules to Be Applied to BMS’ CAR-T Therapy Abecma: Chuikyo
January 27, 2022
- PMDA to Place Top Priority on Safety Measures under Proposed Emergency Approval System: Chief Executive
January 25, 2022
- Lagevrio Should Not Be Given to Asymptomatic COVID Patients: MHLW
January 25, 2022
- Japan to Import Pfizer’s Pediatric Vaccine Next Month, Inoculations to Begin in March: Minister
January 25, 2022
- MHLW Panel Backs Wholesaler Data Use to Monitor Vaccine Shortages in Public Programs
January 25, 2022
- Providing Info on Investigational Drugs on Company Websites Violates PMD Law: MHLW
January 25, 2022
- Lilly’s Retevmo Up for PAFSC Review for Thyroid Cancer on Feb. 4; Lenvima-Keytruda Combo on Agenda for RCC
January 24, 2022
- No Major Safety Concerns for COVID-19 Jabs: MHLW Panels
January 24, 2022
- Promote Both Pfizer/Moderna Vaccines for Boosters: Health Minister
January 24, 2022
- Veklury Allowed for Administration in Homebound Patients
January 24, 2022
- JPMA Calls for Data Consolidation under Medical Infrastructure Law: Govt Hearing
January 24, 2022
- MHLW Approves Lilly’s Migrane Drug Reyvow, Amgen’s KRAS Inhibitor and More
January 21, 2022
- Pfizer’s Comirnaty Bags Japan Approval for Ages 5-11; Actemra OK’ed for COVID-19
January 21, 2022
- Govt Panel Compiles Draft Proposal for Bill to Bolster Supply Chains for Drugs, Essential Resources
January 21, 2022
- Pfizer’s Comirnaty Clears Key Panel for Ages 5-11; Actemra Set for COVID-19 Nod
January 21, 2022
- Chuikyo OKs Revised NHI Pricing Rules for FY2022 Price Revision
January 20, 2022
- Macroeconomic Indexing Lacks Perspectives to Promote Innovation, Improve Care: MHLW Bureau Chief
January 20, 2022
- Japan to Beef Up Pharma Supply Chain through Economic Security Bill
January 19, 2022
- Re-Pricing to Hit 23 Drugs in April; Takecab, GLP-1s, Vyndaqel/Vynmac, and More
January 19, 2022
- LDP Lawmakers Want Specific Definitions for Emergency Approval Prerequisites
January 18, 2022
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…